CSI Market
Sign In | Register

Can fite Biopharma Ltd (CANF) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access CANF Annual Cash Flow →
Cash flow patterns shown here provide context for understanding Can fite Biopharma Ltd's ability to sustain operations and capital deployment.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Dec 31 2025)
12 Months 		0 0 0 (Dec 31 2024)
Operating Activities
Income-9.83
Depreciation & amortization0.02
Amortization of Other Assets0.00
Increase (Decrease) in Deferred Revenue-0.41
Restructuring & Impairment Charges0.05
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets0.00
Share-based Compensation0.34
Income (Loss) from Equity Method Investments0.00
Financial Instruments and Foreign Currency Transaction0.00
Increase In Accounts Receivable Prepaid Expenses And Lease Deposit-
Increase Decrease In Account Payable Trade-
Increase Decrease In Deferred Revenues-
Increase Decrease In Other Account Payables-
Increase Decrease In Change In Other Receivables-
Increase Decrease In Sharebased Payment-
Operating Lease Right Of Use Asset Amortization Expense-
Increase Decrease In Operating Lease Liability-
Changes In Fair Value Of Short Term Investment-
Income taxes0.00
Losses/ -gains on Investments net0.00
Increase (Decrease) in Accrued Interest Receivable, Net0.00
Accounts Payable0.54
Accrued Expense0.00
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets-0.20
Other Working Capital0.00
Other Noncash Income (Expense)-0.04
Other net0.00
Payments for (Proceeds from) Other Operating Activities0.00
Discontinued operations0.00
Net Cash flow from Operating Activities-8.95
Investing Activities
Capital Expenditures0.00
Sale of Capital Items0.00
Payments for (Proceeds from) Short-term Investments, Total0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Withdrawalinvestment In Shortterm Deposits Net-
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments to Acquire Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities0.00
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.45
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock6.71
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net0.00
Increase Decrease In Cash And Cash Equivalents-
Right Of Use Asset Obtained In Exchange For Operating Lease Liability-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities9.64
Effect of exchange rate on cash flow0.01
Discontinued operations0.00
Free Cash Flow-8.95
Total Cash Flow0.70
4 historic quarters locked

Sign in to unlock the full Can fite Biopharma Ltd cash flow history.

Sign In Create Free Account

About Can Fite Biopharma Ltd Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 20-F filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001213900-26-034447

Figures are derived from filed reports and may be restated. Historical data is subject to revision.